Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 36353 results found since Jan 2013.

Overall survival advantage of chemotherapy and radiotherapy in the perioperative management of large extremity and trunk soft tissue sarcoma; a large database analysis
Intergroup 9514 reported promising outcomes with neoadjuvant chemoradiotherapy for large extremity/trunk soft tissue sarcoma (ESTS). One decade later, optimum integration of chemotherapy and radiotherapy into the perioperative management of ESTS remains to be defined.
Source: Radiotherapy and Oncology - August 1, 2017 Category: Radiology Authors: Omar Mahmoud, Ahmet Tunceroglu, Ravi Chokshi, Joseph Benevenia, Kathleen Beebe, Francis Patterson, Thomas F. DeLaney Tags: Original article Source Type: research

PET/CT in Esophageal Carcinoma: Applications and Limitations
Squamous cell carcinoma (SqCC) and adenocarcinoma represent approximately 98 % of esophageal malignant tumors. During the last 30 years, the incidence of adenocarcinoma has increased in Western countries (including the USA) where adenocarcinoma currently represents more than 60% of esophageal malignancies, although, worldwide, SqCC continues to be the predominant histologic type. Integrated positron emission tomography (PET)/CT with 2-[fluorine18] fluro-2-deoxy-D-glucose (FDG) is used in many institutions routinely as a tool in the initial staging and then repeated after therapy for the assessment of response to neoadjuvan...
Source: Seminars in Ultrasound CT and MRI - August 8, 2017 Category: Radiology Authors: Sonia L. Betancourt Cuellar, Diana P. Palacio, Marcelo F. Benveniste, Brett W. Carter, Wayne L. Hofstetter, Edith M. Marom Source Type: research

Neoadjuvant therapy for localized and locally advanced renal cell carcinoma
Neoadjuvant Targeted Molecular Therapy in the setting of localized and locally advanced renal cell carcinoma has emerged as a strategy to render primary renal tumors amenable to planned surgical resection in settings where radical resection or nephron-sparing surgery was not thought to be safe or feasible. Presurgical tumor reduction has been demonstrated in a number of studies including a recently published randomized double-blind placebo-controlled study, and an expanding body of literature suggests benefit in select patients.
Source: Urologic Oncology: Seminars and Original Investigations - August 9, 2017 Category: Urology & Nephrology Authors: Ahmet Bindayi, Zachary A. Hamilton, Michelle L. McDonald, Kendrick Yim, Frederick Millard, Rana R. McKay, Steven C. Campbell, Brian I. Rini, Ithaar H. Derweesh Tags: Seminars article Source Type: research

Osteopontin and vasculogenic mimicry formation are associated with response to neoadjuvant chemotherapy in advanced breast cancer
Source: OncoTargets and Therapy - August 18, 2017 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Positron Emission Tomography / Computed Tomography in Esophageal Carcinoma: Applications and Limitations
Squamous cell carcinoma and adenocarcinoma represent approximately 98% of esophageal malignant tumors. During the last 30 years, the incidence of adenocarcinoma has increased in Western countries (including the USA) where adenocarcinoma currently represents more than 60% of esophageal malignancies, although, worldwide, squamous cell carcinoma continues to be the predominant histologic type. Integrated positron emission tomography or computed tomography with 2-[fluorine18] fluro-2-deoxy-d-glucose is used in many institutions routinely as a tool in the initial staging and then repeated after therapy for the assessment of res...
Source: Seminars in Ultrasound CT and MRI - August 8, 2017 Category: Radiology Authors: Sonia L. Betancourt Cuellar, Diana P. Palacio, Marcelo F. Benveniste, Brett W. Carter, Wayne L. Hofstetter, Edith M. Marom Source Type: research

Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy
(Abstracted from Obstet Gynecol 2017;129(6):979–985) Thromboembolism in patients with ovarian and other cancers is associated with lower survival and poor quality of life. The estimated incidence of venous thromboembolism (VTE) among patients with ovarian cancer (OC) is 10% to 22%.
Source: Obstetrical and Gynecological Survey - September 1, 2017 Category: OBGYN Tags: Gynecology: Gynecologic Oncology Source Type: research

Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study
Outcomes of neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder carcinoma (MIUBC) should be improved. Sorafenib was combined with gemcitabine and cisplatin chemotherapy (SGC) in an open-label, single-arm, phase 2 trial (NCT01222676).
Source: Urologic Oncology: Seminars and Original Investigations - September 11, 2017 Category: Urology & Nephrology Authors: Andrea Necchi, Salvatore Lo Vullo, Daniele Raggi, Federica Perrone, Patrizia Giannatempo, Giuseppina Calareso, Elena Togliardi, Nicola Nicolai, Luigi Piva, Davide Biasoni, Mario Catanzaro, Tullio Torelli, Silvia Stagni, Maurizio Colecchia, Adele Busico, M Tags: Original article Source Type: research

Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
The incidence of bladder cancer has increased in the past decade, and mortality from bladder cancer remains a substantial public health burden. After 3 decades of minimal progress in the treatment of advanced-stage disease, recent advances in the genomic characterization of urothelial cancer and breakthroughs in bladder cancer therapeutics have rejuvenated the field. This review highlights the landmark clinical trials of chemotherapy in both the neoadjuvant and advanced or metastatic urothelial carcinoma settings.
Source: Mayo Clinic Proceedings - October 1, 2017 Category: Internal Medicine Authors: Karthik V. Giridhar, Manish Kohli Tags: Symposium on neoplastic hematology and medical oncology Source Type: research

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients
Recent years have seen standardization of the anatomic definitions of pancreatic adenocarcinoma, and increasing utilization of neoadjuvant therapy (NAT). The aim of the current review was to summarize the evid...
Source: World Journal of Surgical Oncology - October 10, 2017 Category: Cancer & Oncology Authors: Mashaal Dhir, Gautam K. Malhotra, Davendra P.S. Sohal, Nicholas A. Hein, Lynette M. Smith, Eileen M. O ’Reilly, Nathan Bahary and Chandrakanth Are Tags: Research Source Type: research

Plasticity in muscle-invasive bladder cancer before and after cisplatin-based neoadjuvant chemotherapy
Cisplatin-based neoadjuvant chemotherapy (NAC) induces a wide spectrum of responses and outcomes in patients with muscle-invasive bladder cancer (MIBC). Here, we investigate the biological and clinical characteristics of matched pre- and post-NAC tumors.
Source: Urologic Oncology: Seminars and Original Investigations - October 1, 2017 Category: Urology & Nephrology Authors: Roland Seiler, Ewan A. Gibb, Mandeep Takhar, Kim Van Kessel, Bas W.G. van Rhijn, Brian Winters, James Douglas, Qiqi Wang, Voleak Choeurng, Nicholas Erho, Christine Buerki, Elai Davicioni, Gottfrid Sj ödahl, George N. Thalmann, Ellen C. Zwarthoff, Joost L Source Type: research

Comparison of cellular composition and Expression of PD-L1/PD1 in urine and blood cells from patients with muscle –invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy
To reactivate the antitumor immune response in muscle invasive bladder cancer (MIBC) is necessary to decipher the immunological status of these patients. Here, we compared cellular and molecular composition of urine and blood in two groups of patients segregated according to their radical treatment (Neoadjuvant chemotherapy+cystectomy vs. upfront cystectomy).
Source: Urologic Oncology: Seminars and Original Investigations - October 1, 2017 Category: Urology & Nephrology Authors: Oscar Rodriguez Faba, Elisabet Cant ó, Alba Sauch, Carlos Zamora, Joan Palou, Pablo Maroto, Silvia Vidal Source Type: research

Association between epithelial tumor markers ’ trends during the course of treatment and oncological outcomes in urothelial bladder cancer
We previously reported that elevated pre-cystectomy serum levels of epithelial tumor markers predict worse oncological outcome in patients with invasive bladder cancer (BC). Herein, we evaluated the effect of neoadjuvant chemotherapy (NAC) on elevated tumor marker levels and their association with oncological outcomes. We also evaluated elevation of TM levels during follow-up and their predictive role in tumor recurrence.
Source: Urologic Oncology: Seminars and Original Investigations - October 1, 2017 Category: Urology & Nephrology Authors: Soroush T. Bazargani, Thomas Clifford, Hooman Djaladat, Anne Schuckman, Sarmad Sadeghi, Tanya Dorff, David Quinn, Siamak Daneshmand Source Type: research

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial
The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as ...
Source: Trials - October 25, 2017 Category: General Medicine Authors: Wei Wu, Heran Deng, Nanyan Rao, Na You, Yaping Yang, Minghui Cao and Jieqiong Liu Tags: Study protocol Source Type: research

A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer
This study aimed to comprehensively analyze the oncological long-term outcomes of trimodal therapy (TMT) and radical cystectomy (RC) for the treatment of muscle-invasive bladder cancer (BC) with or without neoadjuvant chemotherapy (NAC).
Source: Urologic Oncology: Seminars and Original Investigations - October 25, 2017 Category: Urology & Nephrology Authors: Omar Fahmy, Mohd Ghani Khairul-Asri, Tina Schubert, Markus Renninger, Rohan Malek, Hubert K übler, Arnulf Stenzl, Georgios Gakis Tags: Review article Source Type: research

Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis
The objective in this study is to analyze the safety of BCS in the management of LABC in patients with good response to NACT. Methods: We searched the electronic databases of Medline (Pubmed) and Cochrane Library for reports on local recurrence (LR), regional recurrence (RR), distant recurrence (DR), 5-year disease-free survival (DFS) or 5-year overall survival (OS) in patients with LABC receiving BCS or mastectomy (MT) and with good response to NACT. Based on the research results, we conducted a meta-analysis using Review Manager 5.3. Results: Our study showed that 16 studies with a combined total of 3531 patients, ...
Source: Medicine - October 1, 2017 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research